First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report

ALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. Endothelial to mesenchymal transformation with SCLC development is an AL...

Full description

Bibliographic Details
Main Authors: Umair Majeed, MD, Shenduo Li, MD, PhD, Karan Seegobin, MBBS, Aziza Nassar, MD, Rami Manochakian, MD, Yujie Zhao, MD, PhD, Yanyan Lou, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:JTO Clinical and Research Reports
Subjects:
Case report
ALK-EML4
ALK-positive NSCLC
Small cell transformation
ALK I1171T mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000760

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000760

Similar Items